respiratory disease

Lung and airway diseases such as asthma, COPD and cystic fibrosis: drugs and devices for them.

Theme · 10 companies · 3 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • AMGN Amgen

    Sells it 4%, $1.5B a year“TEZSPIRE is currently approved for the treatment of severe uncontrolled asthma (SUA) in the United States, Europe, Japan and more than 70 countries across the globe.”

    Latest 10-QQ3 FY2026 ·

    Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.

    • Revenue$10.4BYoY +8.5%
    • Net income$3.9BYoY +20.1%
  • ARMP Armata Pharmaceuticals, Inc.

    In development“Our first phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa (“ P. aeruginosa”) .”

    Latest 10-QQ3 FY2026NegativeBankruptcy / going concern ·

    AP-SA02 advances toward Phase 3 with FDA support and expanded MTEC funding, but a cash shortfall threatens development.

    • Revenue$3.2MYoY +173.6%
    • Net income$54.9Mvs −$26.7M year ago
  • BBTX Bambusa Therapeutics, Inc.

    In development“We are currently evaluating BBT002 for the treatment of chronic obstructive pulmonary disease (“COPD”) in our global Phase 1 clinical trial in the United States, Australia, Europe, Georgia, and New Zealand (“Global BBT002 Study”) and our Phase 1/2a clinical trial for COPD in China (“China COPD Study”).”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernAccounting issueImpairment / charge ·

    Develops dual-target antibodies for eczema and respiratory diseases; $169M raise funds trials of BBT001 and BBT002.

  • DHR Danaher Corporation

    Sells it“Diagnostics core sales excluding respiratory testing rose 7.0% in Q3 and 5.0% in 9M.”

    Latest 8-KPositiveEarningsGuidance raised ·

    Improving end markets accelerated core growth outside respiratory testing; FY2026 adjusted EPS guidance rose to $8.57–$8.62.

  • INVA Innoviva, Inc.

    Sells it 57%, $236.5M a year“In November 2002, we entered into our LABA Collaboration Agreement with GSK to develop and commercialize once‑daily products for the treatment of chronic obstructive pulmonary disease (“COPD”) and asthma.”

    Latest 10-QQ3 FY2026Positive ·

    XACDURO and GIAPREZA lift U.S. hospital sales; Armata markdowns overwhelm stronger operating earnings

    • Revenue$106.1MYoY −1.6%
    • Net income−$73.9Mvs $89.9M year ago
  • ISRG Intuitive Surgical

    Supplies it“In 2019, the FDA cleared our Ion endoluminal system, which is a flexible, robotic-assisted, catheter-based platform that utilizes instruments and accessories for which the first cleared indication is minimally invasive biopsies in the lung.”

    Latest 8-KLeadership change ·

    Humana insurance chief Aaron Martin appointed independent director, expanding the board effective Jan. 1, 2027.

  • MRK Merck & Co.

    Sells it <1%, $178.0M a year“Ohtuvayre (ensifentrine), an inhaled PDE3/4 inhibitor indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.”

    Latest 8-KLeadership change ·

    Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.

  • NUOX NuvOx Therapeutics, Inc.

    In development“ARDS is a respiratory condition in which patients’ lungs are compromised, and they cannot imbibe enough oxygen through normal inhalation.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernRestatementAccounting issue ·

    Intravenous oxygen drug developer seeks $20M gross at IPO midpoint to advance NanO₂ trials, with glioblastoma results the next major test

  • VRTX Vertex Pharmaceuticals

    Sells it“The CF franchise remained the largest revenue source.”

    Latest 10-QQ3 FY2026Positive ·

    Crinetics adds an endocrine franchise, but deal costs and launch spending squeeze profit despite ALYFTREK-led sales growth.

    • Revenue$3.4BYoY +11.8%
    • Net income$653.6MYoY −39.6%
  • WWB WINDWARD BIO GROUP AG

    In development“WIN378 is initially being developed for the treatment of respiratory diseases with a focus on asthma and COPD.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops long-acting antibodies for asthma and other inflammatory diseases; $175M raise funds trials led by WIN378’s potential twice-yearly dosing

Feedback